AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Oct 31, 2025
30604_dirs_2025-10-31_7fa1e49a-24ab-4657-8a3f-9924887f31cc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-10-29
Reporting Person: MCCORMICK FRANK (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-29 | Common Stock | S | 111755 | $65.4764 | Disposed | 766583 | Indirect |
| 2025-10-29 | Common Stock | S | 31116 | $66.1958 | Disposed | 735467 | Indirect |
| 2025-10-29 | Common Stock | S | 3497 | $67.5235 | Disposed | 731970 | Indirect |
| 2025-10-29 | Common Stock | S | 8598 | $68.5026 | Disposed | 723372 | Indirect |
| 2025-10-29 | Common Stock | S | 43393 | $69.2358 | Disposed | 679979 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 83275 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.
F2: Represents the weighted average sale price of the shares sold from $65.00 to $65.999 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: Represents the weighted average sale price of the shares sold from $66.00 to $66.9875 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4: Represents the weighted average sale price of the shares sold from $67.00 to $67.996 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5: Represents the weighted average sale price of the shares sold from $68.005 to $68.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F6: Represents the weighted average sale price of the shares sold from $69.00 to $69.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.